The Clinical Research Into Gastrodin Sustained-release Tablets On Patients With Migraine

ObjectiveThrough the observation of gastrodin sustained-releasetablets and gastrodin common tablet in the treatment of mig-raine patients; Comparison to improve patients’ clinicalsymptoms and the incidence of adverse reactions in the processof taking the drugs, subjective feeling satisfaction and con-venient taking the loss due to poor patients medication comp-liance rate. while taking the medicine; and meanwhile, obser-ving patients’ before and af-ter-medicine’s level changeof interleukin-17(IL-17) and interleukin-4(IL-4), this paperdiscusses the possible mech-anism of action of the gastrodintablet in the treatment of migraine, and has provided the newmentality for the traditi-onal Chinese and western me-dicinetreatment of migraine.Methods60migraine patients in the neurology clinic of Wuhan Gen-eral Hospital of Guangzhou Military Command from June,2012to January2013were included into survey. According to randomnumber table,60patients were divided into two groups:30patients in treatment group and30patients in control group. The general clinical data difference such as age, gender, co-urse of disease, frequency of headache, headache place was notstatistically significant (P>0.05).And determination of blankgroup of30cases of healthy person serum IL-17and IL-4levels.The gastrodin sustained-release tablets was taking in trea-tment group: one tablet each time (total300mg), twice a day,half an hour after meals; while the gastrodin common tablet wastaking in controlled group:4tablets each time (total300mg),three times a day. Treatment was for6weeks.All pati-entsshall not take any other analgesic drugs during the medication.Both two groups filled the headache diary (see attachment) ontime when the treatment began. The intensity of headache(VAS)，frequency of headache，duration，simultaneous phenomenon wereassessed before treatment and6weeks after treatment respec-tively. At the same time, the blood samples were taken fromall the patients to test the IL-17&IL-4data before treatmentand6weeks after treatment respectively. Also,30healthyindividuals from Center of Health Examination were tested theIL-17&IL-4data.The research data were statistically analyzed using SPSS18.0statistical software. The normally distributed data fromthe test of normality and homogeneity of variance test wereexpressed as mean±standard deviation.Analysis of variancewas used to compare each group, select One-way ANOVA statistics.P <0.05(or P <0.01) difference was statistically significant,and corresponding chart was draw.Results1Both medicine treatment group and control group patientsafter curative effect are distinct, fewer headache, headach -e can alleviate, headache duration, reduce accompanying sy-mptoms.Hower,the treatment group in the incidence of adver-se reactions,subjective feeling taking convenience and sat-isfaction due to poor patients medication compliance rateoflost to follow-up were better than that in control group.2The IL-17of the treatment group reduced from277.86±37.74pg/ml(before treatment)to245.47±40.39pg/ml(after treatment); the IL-17of the control group reduced from275.44±41.45pg/ml(before treatment)to239.90±45.95pg/ml (after treatment); while theIL-17of the healthy individuals from Center of Health Examination was244.26±45.04pg/ml.Befo-re drug treatment group compared with healthy group, with statistical significance(P<0.01),the control group before medicat-ion compared with healthy group,with statistical significa-nce(P<0.01),treatment group compared with healthy group,the medicine has no statistically significant differe-nce(P>0.05),the drug was control group compared with healt-hy group,there was no statistically significant difference(P>0.05).3The IL-4of the treatment group increased from56.97±9.67pg/ml(before treatment)to68.52±10.37pg/ml (after treatment);the IL-4of the control group increased from57.56±9.44ng/ml(before treatment)to67.71±11.44pg/ml (after treatment);while the IL-4of the healthy individuals from Center of HealthExamination was74.56±11.32pg/ml. Before drug treatmentgroup compared with healthy group, with statistical significan-ce(P<0.01),the control group before medication compared withhealthy group,with statistical significance(P<0.01), treatme-nt group compared with healthy group,the medicine has no st -atistically significant difference(P>0.05),the drug was con-trol group compared with healthy group,there was no statistica-lly significant difference(P>0.05).Conclusion1Gastrodin sustained-release tablets can obviously alleviate clinical symptoms of migraine, and zyban incidence of adverse reactions in the use of drugs, medication convenienceand satisfaction due to poor patients medication compliance rate of lost to follow-up, etc is better than that of ordinary tablets.2The sustained-release tablets can reduce the IL-17levelwhile increase the IL-4level of migraine patients, which caninhibit the expression of inflammatory factors, weaken theneurogenic inflammation, reduce neurotoxi-city from the cells,thus play the role of anti-migraine.